Gemoscan Canada, Inc. (Gemoscan) is engaged in the provision of products and solutions to the food intolerance market. Gemoscan owns and markets the Hemocode System, which is a lifestyle solution that with a blood test detects and provides solutions for the treatment of food intolerances. Its market segments include consumers, which include treatment seekers, and health and diet conscious adults; practitioners and administrators, such as medical doctors, naturopaths, dieticians, nutritionists, homeopaths and chiropractors, clinics and health clubs; business to business, and retail, which includes drugs and grocery stores, and in-store health clinics. Gemoscan�s property includes USPTO 11/364,273 chemiluminescence technology. Its Hemocode product is sold to healthcare practitioners, pharmacies, insurance companies, specialty retail and service and Internet. Effective August 14, 2013, Gemoscan acquired the entire interest of Physiomed Kennedy Inc, an owner and operator of a clinic.